Lucid Diagnostics Inc. (LUCD): Price and Financial Metrics


Lucid Diagnostics Inc. (LUCD): $2.63

0.10 (+3.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LUCD Stock Price Chart Interactive Chart >

Price chart for LUCD

LUCD Price/Volume Stats

Current price $2.63 52-week high $13.52
Prev. close $2.53 52-week low $1.69
Day low $2.51 Volume 47,651
Day high $2.69 Avg. volume 161,861
50-day MA $2.10 Dividend yield N/A
200-day MA $0.00 Market Cap 99.76M

Lucid Diagnostics Inc. (LUCD) Company Bio


Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.


LUCD Latest News Stream


Event/Time News Detail
Loading, please wait...

LUCD Latest Social Stream


Loading social stream, please wait...

View Full LUCD Social Stream

Latest LUCD News From Around the Web

Below are the latest news stories about Lucid Diagnostics Inc that investors may wish to consider to help them evaluate LUCD as an investment opportunity.

PAVmed Appoints Shaun O’Neil as Chief Operating Officer

NEW YORK, February 24, 2022--PAVmed appoints Shaun O’Neil as Chief Operating Officer, overseeing corporate operations and commercial activities across PAVmed and its subsidiaries.

Yahoo | February 24, 2022

Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors

NEW YORK, February 15, 2022--PAVmed appoints prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors.

Yahoo | February 15, 2022

Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference

Lucid Diagnostics Inc. (NASDAQ: LUCD ) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM , PAVMZ)) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference on February 17, 2022, at 8:00 AM EST. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest. About Lucid Diagnostics Lucid Diagnostics Inc. (NASDAQ: LUCD ) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ: PAVM ). Lucid is focused on the millions of patien...

Benzinga | February 10, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | January 19, 2022

PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team

NEW YORK, January 12, 2022--PAVmed and Lucid Diagnostics welcome new full-time investor relations team.

Yahoo | January 12, 2022

Read More 'LUCD' Stories Here

LUCD Price Returns

1-mo 32.83%
3-mo -9.31%
6-mo -41.81%
1-year N/A
3-year N/A
5-year N/A
YTD -51.02%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4795 seconds.